Heyu-B announced that Shanghai Heyu Biomedical Technology Co., Ltd., a subsidiary of the company, announced that its highly selective small molecule FGFR2/3 inhibitor ABSK061 has successfully completed the first patient administration in a phase II clinical trial for children with achondroplasia aged 3-12.

Heyu-B announced that Shanghai Heyu Biomedical Technology Co., Ltd., a subsidiary of the company, announced that its highly selective small molecule FGFR2/3 inhibitor ABSK061 has successfully completed the first patient administration in a phase II clinical trial for children with achondroplasia aged 3-12.